Best Fit Profiles
- anti-glycation protocols and metabolic support in diabetes-adjacent contexts
Anti-glycation and cellular protection
Carnosine
Carnosine is a dipeptide with antioxidant and anti-glycation properties. Human trials show modest effects on glucose control, AGE formation, and kidney function in diabetic populations. Longevity data is preliminary.
Evidence Level B
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Modest reduction in glycation markers and oxidative stress; stronger data in metabolic disease contexts
- Safety
- Low Risk
Some individuals experience mild paresthesia at higher doses; histidine and beta-alanine are precursors and may be more cost-effective.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 1000-2000 mg
- Timing
- With meals
- Protocol Duration in Studies
- 12+ weeks for glycation endpoints
Carnosine is rapidly broken down by carnosinase; delayed-release or sustained forms may improve delivery.